Lista de obras -

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

artículo científico publicado en 2006

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

artículo científico publicado en 2008

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

artículo científico publicado en 2007

A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial ⬇️

artículo científico publicado el 11 de marzo de 2011

A proof of concept for structure-based vaccine design targeting RSV in humans

scientific article published on 01 August 2019

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial

artículo científico publicado en 2017

Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection

artículo científico publicado en 2017

Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary Report

artículo científico publicado en 2014

Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

artículo científico publicado en 2016

DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial ⬇️

artículo científico publicado el 8 de abril de 2013

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials ⬇️

artículo científico publicado el 3 de octubre de 2011

Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial

scientific article published on 01 April 2020

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

artículo científico publicado en 2020

Influenza Virus H5 DNA Vaccination Is Immunogenic by Intramuscular and Intradermal Routes in Humans ⬇️

artículo científico publicado el 5 de septiembre de 2012

Phase 1 study of pandemic H1 DNA vaccine in healthy adults

artículo científico publicado en 2015

Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost

artículo científico publicado en 2015

Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)

artículo científico publicado en 2014

Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

artículo científico publicado en 2016

Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine

artículo científico publicado en 2013

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

artículo científico publicado en 2016

Randomization to standard and concise informed consent forms: Development of evidence-based consent practices ⬇️

artículo científico publicado el 20 de abril de 2012

Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial

scientific article published on 28 August 2019

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.

artículo científico publicado en 2018

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals

artículo científico publicado en 2006

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

artículo científico publicado en 2017

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

article by Martin R Gaudinski et al published 2 March 2019 in The Lancet

Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire

artículo científico publicado en 2013

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

artículo científico publicado en 2015

Lista de obras de

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial ⬇️

A proof of concept for structure-based vaccine design targeting RSV in humans

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial

Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection

Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary Report

Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial ⬇️

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials ⬇️

Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Influenza Virus H5 DNA Vaccination Is Immunogenic by Intramuscular and Intradermal Routes in Humans ⬇️

Phase 1 study of pandemic H1 DNA vaccine in healthy adults

Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost

Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)

Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

Randomization to standard and concise informed consent forms: Development of evidence-based consent practices ⬇️

Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection